Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, president ... gift of $100 million from The Marie-Josée and ... new laboratory building that will be the centerpiece ... Marie-Josée and Henry R. Kravis Research Building, two ... Drive, spanning approximately three city blocks following the ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... 22 Techne Corporation,s,(Nasdaq: TECH ) consolidated net ... to $28.6 million or $.74 per diluted share,compared with ... quarter ended,September 30, 2007. Net earnings as a percentage ... of last year to 41.2% for the quarter ended,September ...
... Inc.,(Nasdaq: MDVN ) today announced that the ... its collaboration with,Pfizer Inc. expired on October 20, ... to jointly develop and commercialize,Dimebon for the treatment ... waiting period triggers an up-front payment to Medivation,of ...
... ,silent killers, such as ... Screenings provide potentially life-saving data, including actual images ... and their doctors ... Oct. 22 HealthYes!(TM), based in Austin,is a premier ...
Cached Biology Technology:Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 5Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 3HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 4HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 5HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 6HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 7
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... (March 14, 2012) A research team has identified ... in gene expression, within reprogrammed skin cells. These signatures ... reprogrammed skin cells or induced pluripotent stem cells (iPSCs), ... how the expression of the protein is controlled brings ...
... A new research survey conducted by the Center for ... Center shows the Bangladeshi community in New York City experiences ... and lack of diabetes awareness. The study, published in the ... Health , also found the Bangladeshi community has an interest ...
... Scientists at Johannes Gutenberg University Mainz (JGU) in ... proteins. Detailed knowledge of the dynamics of proteins is ... that occur on the molecular level. To date, this ... with fluorescent substances, but unfortunately this changes the proteins ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2New study shines light on barriers to diabetes care in NYC Bangladeshi community 2Gold nanoantennas detect proteins 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: